Q32 Bio Reports Positive Toppline Results From SIGNAL-AA Trial In Alopecia Areata
Q32 Bio announced positive toppline results from the SIGNAL-AA trial, showing a 35.3% mean reduction in SALT score. The data demonstrates a differentiated safety profile and efficacy that positions bempikibart as a potential next-generation therapy for alopecia areata.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day